Q4 2021 13F Holders as of 12/31/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
125M
-
Number of holders
-
182
-
Total 13F shares, excl. options
-
81M
-
Shares change
-
+12M
-
Total reported value, excl. options
-
$3.83B
-
Value change
-
+$612M
-
Put/Call ratio
-
0.44
-
Number of buys
-
106
-
Number of sells
-
-84
-
Price
-
$47.28
Significant Holders of Apellis Pharmaceuticals, Inc. - Common Stock (APLS) as of Q4 2021
250 filings reported holding APLS - Apellis Pharmaceuticals, Inc. - Common Stock as of Q4 2021.
Apellis Pharmaceuticals, Inc. - Common Stock (APLS) has 182 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81M shares
of 125M outstanding shares and own 64.72% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (12.3M shares), Avoro Capital Advisors LLC (8.56M shares), VANGUARD GROUP INC (7.92M shares), BlackRock Inc. (5.87M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.3M shares), EcoR1 Capital, LLC (4.03M shares), STATE STREET CORP (2.72M shares), Octagon Capital Advisors LP (2.02M shares), RTW INVESTMENTS, LP (1.99M shares), and JENNISON ASSOCIATES LLC (1.86M shares).
This table shows the top 182 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.